Detalles de la búsqueda
1.
Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission.
Int J Gynecol Cancer
; 31(4): 562-568, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33664128
2.
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Lancet Oncol
; 13(9): 869-78, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22884505
3.
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
J Clin Oncol
; 41(16): 2988-2997, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36977286
4.
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
J Clin Oncol
; 41(16): 2998-3008, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37075276
5.
Molecular-targeted therapies: lessons from years of clinical development.
Cancer Treat Rev
; 34(1): 61-80, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17826917
6.
Novel cytotoxic drugs: old challenges, new solutions.
Cancer Treat Rev
; 34(1): 81-91, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17905518
7.
The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.
Cancer Treat Rev
; 33(1): 64-77, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17113234
8.
Trastuzumab (herceptin) for early-stage breast cancer.
Hematol Oncol Clin North Am
; 21(2): 239-56, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17512447
9.
Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission
Int J Gynecol Cancer, v. 31, n. 4, p. 562-568, abr. 2021
Artículo
en Inglés
| SES-SP, SESSP-IBPROD, SES-SP | ID: bud-3667
10.
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
Clin Breast Cancer
; 16(1): 38-44, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26642810
11.
Molecular profiling of a tumor of unknown origin.
N Engl J Med
; 355(10): 1071-2, 2006 Sep 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-16957161
12.
Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).
J Chemother
; 25(4): 239-46, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23906077
13.
The challenging integration of platinum compounds, taxanes, and molecular-targeted therapies in the multidisciplinary treatment of squamous cell carcinoma of the head and neck.
Curr Opin Oncol
; 19(3): 177-9, 2007 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-17414633
14.
Planning cancer control in Latin America and the Caribbean
Lancet Oncol
; 14: 391-436, abril, 2013. tab, map
Artículo
en Inglés
| URUCAN | ID: bcc-4677
15.
OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy.
J Clin Oncol
; 24(32): 5176-7; author reply 5177, 2006 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-17093286
Resultados
1 -
15
de 15
1
Próxima >
>>